Crinetics Pharmaceuticals (CRNX) AI Stock Analysis

• Market Cap: $2.85B
• Dividend Yield: N/A
• Average Volume (3M): 721.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.54
• Revenue Growth: N/A
• EPS Growth: -1.20%
• Country: US
• Employees: 437
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -1.04
• Shares Outstanding: 93,680,130
• 10 Day Avg. Volume: 901,715
• 30 Day Avg. Volume: 721,244
• PEG Ratio: 3.02
• Price to Book (P/B): 2.34
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.14
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 695.73
• Enterprise Value/Gross Profit: 419.73K
• Enterprise Value/Ebitda: -2.28
• 1Y Price Target: $72.50
• Price Target Upside: 134.02% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 54 Neutral
• Price Target: $32.00 ▲(3.29%Upside)

Crinetics Pharmaceuticals has a moderate stock score driven by promising future growth potential from its robust pipeline and strategic advancements. However, significant financial challenges and valuation concerns, including ongoing losses and a negative P/E ratio, pose risks. The mixed technical indicators also reflect uncertainty in the stock's current trend.

Positive Factors

Business Strategy

Crinetics develops drugs internally, progresses them to the clinic, and is working towards commercialization, indicating a strong pipeline and business strategy.

Product Development

Positive physician feedback at ENDO conference set the stage for Palsonify to become the new standard of care for acromegaly.

Regulatory Progress

The PDUFA date for paltusotine remains on track with routine FDA interactions, highlighting confidence in the regulatory process.

Negative Factors

Investor Sentiment

With a commercial launch only a few months away and an earlier-stage pipeline that is heating up, there is disagreement with the notion that there is a news vacuum.

Safety Concerns

There seems to be a significant investor disconnect, stemming from safety concerns with atumelnant in congenital adrenal hyperplasia and a perceived catalyst desert in the future.

Crinetics Pharmaceuticals Business Overview & Revenue Model

Company Description

Crinetics Pharmaceuticals (CRNX) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics targeting endocrine diseases and cancers. The company specializes in developing oral small-molecule drugs that address significant unmet needs in endocrinology, with a pipeline including treatments for conditions such as acromegaly, neuroendocrine tumors, and congenital adrenal hyperplasia.

How the Company Makes Money

Crinetics Pharmaceuticals primarily generates revenue through the development and potential commercialization of its proprietary drug candidates. The company invests in research and development to advance its pipeline through various stages of clinical trials, aiming to obtain regulatory approval for its products. Revenue is expected to be realized upon successful approval and commercialization of these therapies, either through direct sales or partnerships with larger pharmaceutical companies for distribution and marketing. Additionally, Crinetics may engage in strategic collaborations or licensing agreements that provide upfront payments, milestone payments, and royalties based on sales performance.

Crinetics Pharmaceuticals Financial Statement Overview

Summary

Crinetics Pharmaceuticals faces substantial financial challenges, including persistent net losses, negative EBIT and EBITDA margins, and ongoing cash flow issues. The balance sheet shows improvement with strong cash reserves but historical financial instability and negative equity are concerning.

Income Statement

Crinetics Pharmaceuticals has experienced fluctuating revenue with a decline from 2022 to 2023, followed by a sharp drop in 2024. The gross profit margin is consistently high, but net losses persist, indicating ongoing profitability challenges. Negative EBIT and EBITDA margins reflect operational inefficiencies.

Balance Sheet

The company shows a strong equity position with substantial cash reserves and minimal debt. However, negative stockholders' equity in earlier years indicates past financial distress. Current liabilities are relatively low, but the debt-to-equity ratio is a concern due to historical negative equity.

Cash Flow

Operating cash flow remains negative, highlighting potential liquidity challenges. Free cash flow is also consistently negative, though recent financing activities have bolstered cash reserves. Stability in cash flow remains a concern with ongoing operational losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.04M	4.01M	4.74M	1.08M	71.00K
Gross Profit	-1.75M	4.01M	3.35M	-184.00K	-56.93M
EBITDA	-338.85M	-221.51M	-166.90M	-106.78M	-72.59M
Net Income	-298.41M	-214.53M	-159.95M	-106.72M	-72.86M
Balance Sheet
Total Assets	1.43B	635.35M	352.18M	351.01M	183.44M
Cash, Cash Equivalents and Short-Term Investments	1.35B	558.55M	334.43M	333.71M	170.88M
Total Debt	51.72M	51.73M	2.02M	3.07M	4.01M
Total Liabilities	109.79M	96.25M	35.85M	19.07M	14.53M
Stockholders Equity	1.32B	539.11M	-439.17M	-275.25M	-167.61M
Cash Flow
Free Cash Flow	-229.81M	-171.00M	-116.86M	-89.02M	-62.21M
Operating Cash Flow	-225.97M	-166.31M	-115.20M	-88.59M	-62.03M
Investing Cash Flow	-574.82M	-200.41M	-173.98M	-56.48M	217.00K
Financing Cash Flow	1.01B	388.94M	121.96M	252.68M	114.57M

Crinetics Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 30.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRNX, the sentiment is Negative. The current price of 30.98 is above the 20-day moving average (MA) of 30.74, below the 50-day MA of 31.04, and below the 200-day MA of 40.63, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 49.41 is Neutral, neither overbought nor oversold. The STOCH value of 17.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRNX.

Crinetics Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACAD	78 Outperform	$3.78B	16.43	37.24%	―	22.42%	―
APLS	55 Neutral	$2.50B	―	-103.82%	―	48.04%	48.16%
CRNX	54 Neutral	$2.85B	―	-30.84%	―	―	-1.20%
VKTX	53 Neutral	$3.61B	―	-19.99%	―	―	-23.84%
Sector *	52 Neutral	$7.61B	0.04	-62.94%	2.44%	16.14%	0.33%
SRRK	50 Neutral	$3.80B	―	-106.71%	―	―	-22.34%
IMVT	45 Neutral	$3.15B	―	-62.46%	―	―	-43.10%

Crinetics Pharmaceuticals Corporate Events

Crinetics Pharmaceuticals Presents at ENDO 2025 Meeting

On June 30, 2025, Crinetics Pharmaceuticals announced that it will present eight abstracts from its clinical development programs at the Endocrine Society’s Annual Meeting, ENDO 2025, in San Francisco. The presentations will include long-term efficacy and safety data on PALSONIFY for acromegaly, results from a Phase 2 trial of atumelnant for congenital adrenal hyperplasia, and early-stage data on CRN12755 for Graves’ hyperthyroidism. These developments highlight Crinetics’ commitment to addressing unmet needs in endocrine disorders and reinforce its position as a leader in endocrine-focused pharmaceutical innovation.

The most recent analyst rating on (CRNX) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.

Crinetics Pharmaceuticals Unveils Promising Preclinical Pipeline

On June 26, 2025, Crinetics Pharmaceuticals held a Research and Development Day in New York, presenting updates on its preclinical pipeline. Key highlights included the development of CRN12755 for Graves’ disease, CRN10329 for polycystic kidney disease, and CRN09682 for neuroendocrine tumors. The event showcased promising preclinical data and outlined strategic plans for clinical trials, indicating potential advancements in treatment options for these conditions.

The most recent analyst rating on (CRNX) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.

Crinetics Pharmaceuticals Holds Annual Stockholders Meeting

At the annual meeting of Crinetics Pharmaceuticals‘ stockholders held on June 11, 2025, key decisions were made, including the election of three Class I directors for three-year terms, the ratification of BDO USA, P.C. as the independent accounting firm, and the approval of executive compensation. These decisions reflect strong shareholder support and are likely to influence the company’s strategic direction and governance structure.

The most recent analyst rating on (CRNX) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.